Therapeutic potential of targeting group III metabotropic glutamate receptors in the treatment of Parkinson's disease by Duty, Susan
REVIEW
Therapeutic potential of
targeting group III
metabotropic glutamate
receptors in the treatment
of Parkinson’s disease
Susan Duty
King’s College London, Wolfson Centre for Age-Related Diseases, Guy’s Campus, London, UK
Correspondence
Dr Susan Duty, King’s College
London, Wolfson Centre for
Age-Related Diseases, Guy’s
Campus, London SE1 1UL, UK.
E-mail: susan.duty@kcl.ac.uk
----------------------------------------------------------------
Keywords
basal ganglia; group III mGlu
receptors; metabotropic
glutamate receptors; motor
symptoms; neurodegeneration;
Parkinson’s disease; substantia
nigra
----------------------------------------------------------------
Received
19 November 2009
Revised
27 April 2010
Accepted
30 April 2010
----------------------------------------------------------------
Re-use of this article is permitted
in accordance with the Terms
and Conditions set out at
http://www3.interscience.wiley.com/
authorresources/onlineopen.html
Current drugs used in the treatment of Parkinson’s disease (PD), for example, L-DOPA and dopamine agonists, are very
effective at reversing the motor symptoms of the disease. However, they do little to combat the underlying degeneration of
dopaminergic neurones in the substantia nigra pars compacta (SNc) and their long-term use is associated with the
appearance of adverse effects such as L-DOPA-induced dyskinesia. Much emphasis has therefore been placed on ﬁnding
alternative non-dopaminergic drugs that may circumvent some or all of these problems. Group III metabotropic glutamate
(mGlu) receptors were ﬁrst identiﬁed in the basal ganglia a decade ago. One or more of these receptors (mGlu4, mGlu7 or
mGlu8) is found on pre-synaptic terminals of basal ganglia pathways whose overactivity is implicated not only in the
generation of motor symptoms in PD, but also in driving the progressive SNc degeneration. The ﬁnding that drugs which
activate group III mGlu receptors can inhibit transmission across these overactive synapses has lead to the proposal that group
III mGlu receptors are promising targets for drug discovery in PD. This paper provides a comprehensive review of the role and
target potential of group III mGlu receptors in the basal ganglia. Overwhelming evidence obtained from in vitro studies and
animal models of PD supports group III mGlu receptors as potentially important drug targets for providing both symptom
relief and neuroprotection in PD.
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Introduction: unmet therapeutic needs
in Parkinson’s disease
Parkinson’s disease (PD) is the second most
common neurological disorder after Alzheimer’s
and is characterized by motor disturbances such as a
resting tremor, slowness of movement (bradykine-
sia), difﬁculty in initiating movements (akinesia),
rigidity and postural instability. Alongside these
classical motor symptoms, associated problems
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trointestinal disturbances and pain may further
impair the quality of life of individuals with PD.
Although these non-motor symptoms are now
starting to receive the recognition and attention
they deserve (e.g. Chaudhuri and Schapira, 2009),
this review will explore recent advances in
targeting group III metabotropic glutamate (mGlu)
receptors for the treatment of the classical motor
symptoms.
The motor symptoms largely arise through the
progressive degeneration of dopaminergic neu-
rones in the substantia nigra pars compacta (SNc).
These midbrain neurones project to forebrain
regions, most notably the striatum, where the
release of dopamine serves to regulate cortically
driven ﬁring within the basal ganglia thalamocor-
tical motor circuits to ensure proper planning and
execution of movement (Lang and Lozano, 1998).
Current treatments for PD focus on reinstating
striatal dopaminergic transmission through the use
of the dopamine precursor, L-DOPA or dopamine
agonists such as ropinirole or bromocriptine. The
introduction of L-DOPA in the mid-1960s was
undoubtedly a signiﬁcant step forward, bringing
effective relief of early stage motor symptoms
to millions of PD patients worldwide. Similar
symptom relief is now also provided by the range
of available dopamine agonists. However, these
drugs do little to combat the progressive degenera-
tion of dopaminergic neurones in the nigrostriatal
tract that characterizes the pathology of PD. This
failure affects patients’ long-term health since the
increasing doses of drug required to stabilize wors-
ening symptoms evoke disabling adverse effects
including: L-DOPA-induced dyskinesia (LID) which
are involuntary hyperkinetic movements of a
choreic, dystonic or ballistic nature (Marsden and
Parkes, 1977; Fabbrini et al., 2007; Jenner, 2008),
psychosis (Zahodne and Fernandez, 2008) and
aberrant reward-seeking behaviour (Antonini and
Cilia, 2009).
The prevalence of PD increases with age. In a
European survey of nearly 15 000 participants aged
65 years and over, the prevalence of PD (per 100
population of age-matched individuals) increased
with age from 0.6 (65–69 years) up to 3.6 (80–84
years) (de Rijk et al., 1997). With the current global
demographic revolution, the proportion of persons
aged 60 years or over is expected to double to 22%
by 2050 (Department of Economic and Social
Affairs, 2009). The associated predicted increase in
the incidence of PD has led the World Health Orga-
nization to identify this condition as an important
public health issue that will place signiﬁcant burden
on health care resources worldwide (Janca, 2002).
Given the failings of current treatments for PD, it is
not surprising that much emphasis has been placed
on ﬁnding alternative, non-dopaminergic treat-
ments that may offer symptom relief while also
slowing the progressive degeneration and possibly
helping to stave off dyskinesia.
Abnormal ﬁring of basal ganglia
circuits in PD: contribution to clinical
signs and progressive nigral
degeneration
The loss of striatal dopamine innervation in PD
produces opposing downstream changes in ﬁring of
the two main basal ganglia motor pathways by
virtue of their distinct dopamine receptor popula-
tions (Smith et al., 1998; Blandini et al., 2000;
Figure 1). In the direct pathway, loss of dopamine
D1-like receptor stimulation leads to reduced ﬁring
of GABAergic striatal efferents to the basal ganglia
output regions, the substantia nigra pars reticulata
(SNr) and the internal globus pallidus (GPi). In con-
trast, in the indirect pathway, loss of the inhibitory
drive normally maintained through dopamine
D2-like receptor stimulation leads to increased
ﬁring in the GABAergic striatopallidal pathway,
which in turn inhibits GABAergic drive to the sub-
thalamic nucleus (STN), leading to increased ﬁring
of the glutamatergic STN efferents to the SNr/GPi
(Hirsch et al., 2000). This abnormal ﬁring of direct
and indirect circuits culminates in a net increase in
prevailing glutamate levels in SNr/GPi which drives
inhibition of thalamocortical feedback, resulting in
the motor deﬁcits seen in PD (Obeso et al., 2000,
2008). Compensating for overactivity of these path-
ways may therefore combat the motor symptoms
in PD. Indeed, the positive clinical outcomes
including alleviation of motor deﬁcits and reduc-
tion in LIDs seen with surgical procedures such as
subthalamotomy, pallidotomy or deep brain stimu-
lation of the STN or GPi to effectively switch off the
basal ganglia output regions (Lozano, 2003; Rod-
riguez et al., 2007; Benabid et al., 2009) strengthen
the premise that correcting abnormal ﬁring, par-
ticularly in the indirect pathway, holds great
promise. However, a pharmacological means of
normalizing ﬁring of these pathways would have
far more widespread application than surgical
procedures.
The STN not only projects to the basal ganglia
output regions but also sends direct projections
to the SNc (Smith et al. 1990; Iribe et al., 1999;
Figure 1). Therefore, increased ﬁring of the STN
under parkinsonian conditions may lead to a
parallel increase in glutamate release in the SNc.
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the degeneration of dopaminergic neurones in
PD, which is probably a multifactorial process
involving mitochondrial dysfunction, inﬂamma-
tion, altered protein handling and oxidative stress
(Schulz, 2007; Banerjee et al., 2009), this predicted
rise in glutamate release in the SNc is implicated in
the subsequent progression of cell death in PD
(Blandini et al., 1996; Rodriguez et al., 1998). Com-
pensating pharmacologically for overactivity of
pathways within the indirect basal ganglia circuit
may therefore slow progression of degeneration
in PD in addition to combating the symptoms as
outlined above. Preclinical studies in rats showing
that inactivation of the STN, through chemical
(kainic acid) lesioning, reduces nigrostriatal tract
damage induced by the dopaminergic toxin,
6-hydroxydopamine (6-OHDA) (Piallat et al., 1996)
support this suggestion. By virtue of their distribu-
tion, function and successful targeting so far in
preclinical studies, group III mGlu receptors are
looking like promising candidates to meet these
expectations.
Localization and functional effects of
group III mGlu receptors in basal
ganglia circuitry
Group III mGlu receptors are one of three groups of
G-protein-coupled mGlu receptor, all of which are
found within the basal ganglia circuitry and have
been shown to hold promise as targets for treating
PD (reviewed in Conn et al., 2005). Herein, the
nomenclature used for these receptors conforms to
the British Journal of Pharmacology’s Guide to Recep-
tors and Channels (Alexander et al., 2008). These
three groups differ in their sequence homology,
agonist and antagonist pharmacology and in their
signal transduction. Group I mGlu receptors, which
include mGlu1 and mGlu5, couple through Gq/11,
leading to phosphoinositide hydrolysis and
enhanced neuronal excitation (Conn and Pin,
1997). Blockade of these receptors, either by the use
of antagonists or negative allosteric modulators, has
shown great promise in the treatment of PD and
related dyskinetic side effects in rodent and primate
models of PD (Rylander et al., 2009; Yamamoto and
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Figure 1
Schematic representation of the parkinsonian basal ganglia motor loop, showing the location of group III metabotropic glutamate (mGlu)
receptors. The loss of striatal dopamine innervation following substantia nigra pars compacta (SNc) degeneration in Parkinson’s disease (PD)
produces opposing downstream changes in ﬁring of the two main basal ganglia pathways. Thick lines indicate overactive pathways; thin lines
indicate underactive pathways; dotted lines indicate degenerated pathways. In the direct pathway, loss of dopamine D1-like receptor stimulation
reduces ﬁring of GABAergic striatal efferents to the substantia nigra pars reticulata (SNr), while in the indirect pathway, loss of inhibitory D2-like
receptor stimulation leads to increased ﬁring in the GABAergic striatopallidal pathway, which in turn inhibits GABAergic drive to the subthalamic
nucleus (STN), leading to increased ﬁring of the glutamatergic STN efferents to the SNr and SNc. The increased glutamatergic innervation of the
SNr ultimately drives inhibition of thalamocortical feedback, resulting in the motor deﬁcits seen in PD, while the increased glutamatergic
innervation in the SNc may contribute to the progressive SNc degeneration. Group III mGlu receptors (mGlu4, 7 or 8), indicated by black stars,
are found on pre-synaptic terminals of intrinsic basal ganglia pathways where their activation may serve to restrict transmitter release. Receptor
subtypes indicated in bold have been conﬁrmed as functional, while those in red have been shown to lack function. DA, dopamine; Glut,
glutamate.
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other hand, activation of group II mGlu receptors
(comprising mGlu2 and mGlu3), which couple
through Gi/Go leading to inhibition of neuronal
transmission, has also proven effective in some
experimental models of PD (Dawson et al., 2000;
Murray et al., 2002). However, in light of recent
advances in available compounds targeting group III
mGlu receptors (e.g. Niswender et al., 2008b; Engers
et al., 2009; Williams et al., 2009), these receptors
are starting to attract increased attention. This
review will therefore provide a timely, comprehen-
sive account of current evidence surrounding the
target potential of group III mGlu receptors in PD.
Group III mGlu receptors comprise four sub-
types, mGlu4, mGlu6, mGlu7 and mGlu8, with all
but mGlu6 playing important neuromodulatory
roles in the brain (Conn and Pin, 1997). These
Gi/Go-coupled receptors are found predominantly
on pre-synaptic terminals of GABAergic and
glutamatergic neurones where they are involved
in regulating synaptic transmission, most likely
through inhibition of voltage-gated calcium entry
required for triggering transmitter release (Trombley
and Westbrook, 1992; Conn and Pin, 1997). These
receptors have also been demonstrated at post-
synaptic sites in some brain regions where their
signalling through activation of G-protein coupled
inwardly rectifying potassium channels is expected
to produce membrane hyperpolarization (Saugstad
et al., 1996).
Localization of group III mGlu receptors within
the basal ganglia has been unravelled to some
extent through a combination of in situ hybridiza-
tion, immunohistochemistry and electron micros-
copy studies, with each of the three receptors of
interest (mGlu4, 7 and 8) exhibiting a predomi-
nantly pre-synaptic distribution. The most accepted
distribution to date is summarized in Figure 1. In
fact, our understanding of the distribution of mGlu4
and mGlu7 receptors has not changed signiﬁcantly
in the last decade (refer to Rouse et al., 2000 for a
summary at that time). Both mGlu4 and mGlu7
receptors have been found on terminals of the
glutamatergic corticostriatal pathway which,
although not discussed above, is considered to
be overactive in PD and thereby contribute to
increased ﬁring of the indirect BG pathway (Obeso
et al., 2008). mGlu4 and mGlu7 receptors are also
found on terminals of the GABAergic striatopallidal
and striatonigral pathways (Bradley et al., 1999;
Kosinski et al., 1999; Corti et al., 2002) as well as on
excitatory (presumed glutamatergic) terminals in
the SNr (Kosinski et al., 1999; Corti et al., 2002).
While the SNr receives excitatory inputs not only
from the STN but also from the pedunculopontine
nucleus and frontal cortex (Carter, 1982; Kita and
Kitai, 1987; Di Loreto et al., 1992), the presence of
mGlu4 and mGlu7 mRNA in the STN (Testa et al.,
1994; Kosinski et al., 1999; Messenger et al., 2002)
strongly supports their expression on terminals of
STN efferents in the so-called subthalamonigral
pathway. The distribution of mGlu8 receptors in the
basal ganglia is the least well characterized of all.
Expression of mRNA encoding mGlu8 receptors
has been reported in the cortex, striatum and STN
(Messenger et al., 2002), while our unpublished
ﬁndings reveal moderate to high levels of corre-
sponding mGlu8 immunoreactivity in the striatum
and SNr. Therefore, it remains a possibility that
mGlu8 receptors are found on pre-synaptic termi-
nals of corticostriatal, striatonigral or subthalamoni-
gral pathways.
Although group III mGlu receptors are consid-
ered to be predominantly pre-synaptic within the
basal ganglia, very low levels of mGlu7 immunore-
activity have been found at post-synaptic dendritic
sites in both the GP (Bradley et al., 1999; Kosinski
et al., 1999) and striatum (Kosinski et al., 1999).
However, electrophysiological studies found no evi-
dence for a post-synaptic action of group III mGlu
receptors in the GP (Valenti et al., 2003) and any
post-synaptic action in the striatum remains to be
determined. At the present time, therefore, focus
remains ﬁxed on the potential of the pre-synaptic
receptors.
While the existence of group III mGlu receptors
on pre-synaptic terminals of pathways that are
overactive in PD (corticostriatal, striatopallidal and
subthalamonigral) is promising, demonstrating a
functional role for each receptor in regulating
transmission across these synapses is essential to
support their potential as therapeutic targets for
normalizing the activity of basal ganglia pathways
in PD. With the lack of subtype-selective antagonists
available, the only avenue open has been to explore
the actions of subtype-selective agonists. That said,
the task of developing subtype-selective agonists
in the group III mGlu ﬁeld has proven difﬁcult and
it was as recent as 2003 when the ﬁrst subtype-
selective agent, in this case a positive allosteric
modulator (PAM) of mGlu4 receptors, N-phenyl-
7-(hydroxylimino) cyclopropa[b]chromen-1a-
carboxamide (PHCCC), was identiﬁed (Maj et al.,
2003; Marino et al., 2003). The selectivity of PHCCC
along with that of the other compounds discussed
below that have been used to pharmacologically
probe the actions of group III mGlu receptors in the
basal ganglia are documented in Table 1.
There is now a wealth of electrophysiological
evidence supporting a functional role for group III
mGlu receptors in general, in each of the target
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ality has been demonstrated are emphasized in bold.
Considering the corticostriatal pathway ﬁrst of all,
in a corticostriatal slice preparation, activation of
group III mGlu receptors with the broad spectrum
agonists, L-serine-O-phosphate (L-SOP) and L-2-
amino-4-phosphonobutyrate (L-AP4), has been
shown to mediate depression of striatal excitatory
post-synaptic potentials (EPSPs) evoked by cortical
stimulation (Pisani et al., 1997; Cuomo et al., 2009).
This depression of EPSPs is taken to reﬂect inhibi-
tion of glutamate release from corticostriatal termi-
nals. These effects were lost in slices from mGlu4
knockout mice, but were replicated in normal slices
by the novel mGlu4 orthosteric agonist (3S)-3-
[(3-amino-3-carboxypropyl(hydroxyl)-phosphinyl)-
hydroxymethyl]-5-nitrothiophene (LSP1-3081)
(Cuomo et al., 2009), indicating that mGlu4 recep-
tors play a signiﬁcant role in mediating this effect.
Conversely, the mGlu8-selective agonist (S)-3,4-
dicarboxyphenylglycine ((S)-DCPG) did not inhibit
cortically evoked EPSPs in the striatum, suggesting
that mGlu8 receptors, although possibly present, are
not functional at this synapse (Cuomo et al., 2009).
The role of putative mGlu7 receptors in the corti-
costriatal pathway remains to be investigated.
Turning next to the striatopallidal pathway,
where the presence of mGlu4 and mGlu7 receptors
was suggested from the distribution studies, L-AP4
has been shown to mediate inhibition of striatal-
evoked inhibitory post-synaptic currents (IPSCs)
recorded in the GP (Marino et al., 2003; Valenti
et al., 2003), an effect likely explained by inhibition
of GABA release from striatopallidal terminals. In
support of this, our in vivo microdialysis studies indi-
cate that local infusion of L-SOP or L-AP4 inhibits
GABA release in the rat GP (MacInnes and Duty,
2008). The mGlu4 receptor appears crucial in the
striatopallidal pathway, since the L-AP4-mediated
inhibition of IPSCs was lost in slices from mGlu4
knockout mice (Valenti et al., 2003), but was
enhanced in normal slices by the mGlu4 PAM
PHCCC (Marino et al., 2003) and mimicked by the
novel mGlu4 selective agonist LSP1-2111 (Beurrier
et al., 2009). Although an involvement of mGlu7
receptors seems unlikely, given the loss of L-AP4’s
Table 1
Potencies (EC50 in mM) of agonists or positive allosteric modulators at indicated group III mGlu receptors in cell expression systems
mGlu4 mGlu6 mGlu7 mGlu8 Other mGlu targets Reference
AGONISTS
L-AP4 0.2–1 0.2–0.9 >100 0.06–0.9 >1000 (mGlu1,5,2 & 3) Cartmell and Schoepp,
2000
ACPT-I 1.7 10.6 281 5 – Beurrier et al., 2009
LSP1-2111 2.2 1.7 53 66 >100
(mGlu1,5,2)
Beurrier et al., 2009
LSP1-3081 0.16 3.3 419 0.5 n.e Cuomo et al., 2009
AMN082
# >10 (<20%) >10 (none) 0.06–0.3
(90–140%)
>10 (<20%) >10 (mGlu1,5,2 & 3) Mitsukawa et al., 2005
(S)-DCPG 8.8 3.6 >100 0.03 >100 (mGlu2,3,5)
32 (IC50 at mGlu1)
Thomas et al., 2001
POSITIVE ALLOSTERIC
MODULATORS
PHCCC (with 5 mM
l-glutamate)
2.8 >10 >40 >10 3.4 (IC50 at Glu1) 30%
max inhibition
Maj et al., 2003
VU0155041* (with EC20
of l-glutamate)
0.7–0.8 n.e n.e n.e n.e Niswender et al., 2008a
The main group III target for each agent is highlighted in bold while values for known activities at other mGlu receptors are shown for
comparison.
*VU0155041 also displays partial agonist activity with an EC50 2.5 mM at mGlu4 receptors. n.e. = no effect observed with LSP1-3081 or
racemate of VU0155041 (VU0003423).
#AMN082 is an allosteric site agonist. Values in parentheses indicate % increase in GTP g-S binding produced by AMN082 in different cell
lines.
ACPT-I, (1S,3R,4S)-1aminocyclopentane-1,3,4-tricarboxylic acid; AMN082, N,N’-dibenzhydryl-ethane-1,2-diamine dihydrochloride;
(S)-DCPG, (S)-3,4-dicarboxyphenylglycine; L-SOP, L-serine-O-phosphate; LSP1-3081, (3S)-3-[(3-amino-3-carboxypropyl(hydroxyl)-
phosphinyl)-hydroxymethyl]-5-itrothiophene; PHCCC, N-phenyl-7-(hydroxylimino) cyclopropa[b]chromen-1a-carboxamide; VU0155041,
(+/-)-cis-2-(3,5,dichlorphenylcarbamoyl)cyclo-hexanecarboxylic acid.
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(Valenti et al., 2003), until the effects of mGlu7
selective agents have been examined, a functional
role for these receptors cannot be ruled out at this
stage.
Reafﬁrming what was suspected from the distri-
butional data, electrophysiological evidence also
indicates the presence of functional group III mGlu
receptors on terminals of the subthalamonigral
pathway. Thus, L-AP4 depresses STN-evoked EPSCs
in the SNr (Wittmann et al., 2001; 2002), and inhib-
its EPSPs in dopaminergic neurones of the SNc
(Wigmore and Lacey, 1998), most likely reﬂecting
inhibition of glutamate release from STN terminals
in these regions. In support of this, we found that
L-SOP and L-AP4 inhibited depolarization-evoked
release of [
3H]-D-aspartate from slices of rat SN in
vitro and that local intranigral infusion of L-SOP
reduced glutamate release in the SNr in vivo (Austin
et al., 2010). Once again, mGlu4 receptors have
been identiﬁed as one of the functional subtypes,
since STN-evoked EPSCs in dopaminergic neurones
of the SNc were inhibited by the mGlu4 PAM
PHCCC (Valenti et al., 2005). This is consistent
with our ﬁndings that PHCCC potentiates L-AP4-
mediated inhibition of [
3H]-D-aspartate release in
SN slices (Broadstock et al. unpublished). Although
no published reports have examined the effect of
stimulating mGlu7 receptors on STN terminals, our
preliminary data indicate that these receptors act to
inhibit glutamate release in the SN since the mGlu7
allosteric agonist N,N’-dibenzhydryl-ethane-1,2-
diamine dihydrochloride (AMN082; Mitsukawa
et al., 2005) inhibits [
3H]-D-aspartate release in SN
slices. In contrast, a role for pre-synaptic mGlu8
receptors looks unlikely given that activation of
mGlu8 receptors with (S)-DCPG neither inhibited
[
3H]-D-aspartate release in our preliminary studies
(Broadstock et al. unpublished) nor reduced STN-
evoked EPSCs in the SNc (Valenti et al., 2005).
The presence of group III mGlu receptors on
GABAergic striatonigral terminals raises a potential
cause for concern. When activated by L-AP4, these
receptors have been shown to mediate inhibition of
striatal-evoked IPSCs in the SNr (Wittmann et al.,
2002). No subtype-speciﬁc studies have been under-
taken to identify which group III receptors are the
culprits. From a therapeutic standpoint, however,
these receptors are a potential stumbling block since
restricting GABA release in the SNr would exacer-
bate an already compromised striatonigral transmis-
sion and potentially undo the beneﬁts of inhibiting
glutamate release in this region from STN terminals.
Fortunately, current evidence seems to rule out any
likely detrimental effect of activating these receptors
in PD. Electrophysiological studies have shown that
under conditions of dopamine depletion, that is, in
slices taken from animals treated with reserpine to
deplete all catecholamines, while the ability of
L-AP4 to inhibit STN-evoked EPSCs in the SNr is
maintained, its ability to inhibit striatal-evoked
IPSCs in the SNr is lost (Wittmann et al., 2002).
These ﬁndings indicate that under parkinsonian
conditions, the pharmacological effects of group III
mGlu receptors on the desired subthalamonigral ter-
minals most likely override those of the receptors
on striatonigral terminals. The behavioural studies
described below in animal models of PD certainly
appear to back up this supposition.
Given that one or more functional group III
mGlu receptor subtype has been identiﬁed at several
desirable locations in the basal ganglia circuitry,
activation of these receptors has been predicted to
bring about relief of parkinsonian symptoms, by
normalizing ﬁring within the basal ganglia circuitry,
and to offer protection against SNc degeneration, by
reducing glutamate-mediated excitotoxicity (Rouse
et al., 2000; Conn et al., 2005). The remainder of this
review will focus on current evidence obtained in
support of these predictions.
Symptomatic relief following group III
mGlu receptor activation
Targeting of group III mGlu receptors to bring
about symptomatic relief has been studied in a
number of different rodent models of PD. In the
reserpine-treated rat, systemic injection of reserpine
depletes the brain of all monoamines, including
dopamine, and induces akinesia within 12–18 h
that is maintained for up to 48 h. Drug-induced
reversal of akinesia is monitored as an index of
symptomatic efﬁcacy. In the haloperidol-treated
rat, systemic injection of haloperidol produces a
temporary state of catalepsy, the reversal of which
is also taken to indicate symptomatic efﬁcacy of
test drugs. Finally, in the unilateral 6-OHDA-
lesioned rat, akinesia in the forelimb contralateral
to the lesion is manifest as reduced reaching in
cylinder reaching tests, and the ability of drugs to
reverse this akinesia is taken as a measure of symp-
tomatic efﬁcacy. In support of the validity of all
three models, neurochemical or electrophysiologi-
cal ﬁndings support features of increased STN ﬁring
and increased glutamate release in the basal ganglia
output regions, the SNr or entopeduncular nucleus
(the rat homologue of GPi) (You et al., 1996; Biggs
et al., 1997; Vila et al., 1999).
Because of the limited availability of systemically
active group III mGlu receptor agonists or PAMs, the
majority of studies have examined the efﬁcacy of
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clinical relevance, site-directed injections have been
very useful in teasing out which regions of the basal
ganglia circuitry can be targeted to mediate beneﬁ-
cial outcomes. Given the activation of pre-synaptic
group III mGlu receptors in the striatum, GP or SNr
could potentially restrict transmitter release from
overactive pathways to normalize ﬁring of the basal
ganglia circuits and thereby restore movement,
these regions have all been subject to some degree of
investigation.
Targeting the striatum
Intrastriatal injections of the broad spectrum group
III mGlu agonists (1S,3R,4S)-1aminocyclopentane-
1,3,4-tricarboxylic acid (ACPT-I) and L-AP4 have
been shown to produce relief of haloperidol-induced
catalepsy (Konieczny et al., 2007) or to improve aki-
nesia in the 6-OHDA lesioned rat (Cuomo et al.,
2009). These data are consistent with the L-AP4-
mediated depression of cortical-evoked EPSPs in the
striatum (Pisani et al., 1997), indicating that restric-
tion of glutamate release from overactive cortical
inputs likely underlies this symptom relief. Consis-
tent with the electrophysiological ﬁndings, the
involvement of mGlu4 receptors is favoured in this
action, since intrastriatal injection of the orthosteric
mGlu4 agonist, LSP1-3081, reduces akinesia in the
6-OHDA lesioned rat (Cuomo et al., 2009). While
mGlu8 receptors are unlikely to be involved in this
region, given their lack of functional effects noted
above (Cuomo et al., 2009), any positive contribu-
tion from mGlu7 receptors remains to be examined.
Targeting the GP
The GP was one of the ﬁrst regions implicated in
mediating the anti-parkinsonian responses of broad
spectrum group III mGlu agonists. Studies from our
laboratory ﬁrst demonstrated that direct injection of
L-SOP into the GP reversed akinesia in the reserpine-
treated rat (MacInnes et al., 2004). Others have since
conﬁrmed that direct intrapallidal injections of the
broad spectrum agonists, L-AP4 or ACPT-I reversed
reserpine-induced akinesia as well as reversing
haloperidol-induced catalepsy and 6-OHDA-
induced forelimb akinesia (Konieczny et al., 2007;
Lopez et al., 2007). These effects which, when tested,
were blocked by treatment with group III mGlu
receptor antagonists, most likely reﬂect inhibition
of GABA release within the GP (Marino et al., 2003;
Valenti et al., 2003; MacInnes and Duty, 2008)
which is predicted to normalize ﬁring within the
indirect basal ganglia pathway and hence restore
motor activity. The most recent ﬁndings concur
with earlier electrophysiological data (Marino et al.,
2003; Valenti et al., 2003) indicating that mGlu4
receptors play a key role in the GP. Thus, Beurrier
et al. (2009) demonstrated that injection of the
mGlu4 agonist, LSP1-2111 reversed akinesia in the
6-OHDA lesion rat model of PD. In contrast, consis-
tent with the lack of clear evidence favouring the
existence of mGlu8 receptors on striatopallidal ter-
minals, intrapallidal injection of the mGlu8 agonist
(S)-DCPG was ineffective (Lopez et al., 2007; Beur-
rier et al., 2009), ruling out any target potential of
mGlu8 receptors here. Again, a role for mGlu7
receptors in the GP awaits veriﬁcation.
Targeting the substantia nigra pars reticulata
As discussed above, within the SNr, group III mGlu
receptors are found not only on the desired
glutamatergic subthalamonigral terminals but also
on GABAergic striatonigral terminals. This raises the
possibility that activation of these receptors could
produce a number of different outcomes–an e t
inhibition of GABAergic transmission (i.e. inhibi-
tion of striatal-evoked IPSCs), a net inhibition of
glutamatergic transmission (i.e. inhibition of
glutamate-evoked EPSCs) or functional stale-mate
with neither effect dominating. In vitro, Wittmann
et al. (2002) had shown that under conditions of
dopamine depletion, the beneﬁcial action of group
III mGlu receptors to inhibit STN-evoked EPSCs in
the SNr predominated over the potentially detri-
mental action to inhibit striatal-evoked IPSCs. For-
tunately, this phenomenon appears to hold true in
vivo. Under conditions of marked dopamine deple-
tion or dopamine receptor blockade, injections of
broad spectrum group III agonists L-SOP, L-AP4
or ACPT-I into the SNr brought about beneﬁcial
anti-parkinsonian actions including reversal of
reserpine-induced akinesia (MacInnes et al., 2004;
Austin et al., 2010) and haloperidol-induced cata-
lepsy (Konieczny et al., 2007). In light of the above
electrophysiological, release and microdialysis
data, these responses most likely reﬂect receptor-
mediated inhibition of glutamate release from
overactive subthalamonigral neurones. However, in
normal animals, injection of ACPT-I into the SNr
induced catalepsy (Lopez et al., 2007), probably
reﬂecting a predominant effect to inhibit GABA
release from the striatonigral pathway, as noted in
vitro. Of some concern, intranigral injections of
ACPT-I also worsened akinesia in a partial 6-OHDA
lesioned rat model of PD displaying (58%) reduction
in striatal dopamine innervation (Lopez et al.,
2007), implying that even with this level of dopam-
ine loss, the detrimental effects on GABAergic trans-
mission still dominate. Estimations of the threshold
level of nigrsotriatal tract degeneration required for
symptoms to appear in patients vary widely. Some
have estimated a 68% loss of cells in the lateral
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SNc) at the time of symptom onset (Fearnley and
Lees, 1991). Others have estimated, using positron
emission tomography or single photon emission
tomography, that striatal dopamine transporters are
reduced by between 25 and 64% at the point of
symptom onset (Morrish et al., 1998; Booji et al.,
2001; Hilker et al., 2005). This variability makes it
difﬁcult to predict the likely outcome of targeting
group III mGlu receptors in the SNr in the early
stages of PD. Clearly, it will be essential to establish
at what level of lesion development the detrimental
effects of targeting group III mGlu receptors in the
SNr are replaced by the beneﬁcial ones, or indeed
which group III mGlu receptor subtype might be
responsible for the detrimental effects, before the
full impact of this ﬁnding is realized.
The subtype of group III mGlu receptor mediat-
ing these anti-parkinsonian effects in the SNr is
unlikely to be mGlu8, since intranigral injection of
the mGlu8-selective agonist (S)-DCPG failed to
reverse haloperidol-induced catalepsy (Lopez et al.,
2007), in agreement with the lack of in vitro efﬁcacy
with (S)-DCPG in the SN (Valenti et al., 2005).
However, both mGlu4 and mGlu7 receptors remain
as possible targets in the SNr and our preliminary
ﬁndings showing relief of reserpine-induced akine-
sia following intranigral injection of both the
mGlu4 PAM, PHCCC and the mGlu7 allosteric
agonist AMN082 (Broadstock et al. unpublished)
support further investigation of their potential as
drug targets.
Targeting multiple sites simultaneously
While site-directed injections have revealed much
about the basal ganglia regions in which activating
group III mGlu receptors could offer symptomatic
potential in PD, routes of administration that can
target multiple sites simultaneously give a better
indication of the likely translation of these ﬁndings
into therapeutic strategies. So far, positive outcomes
have been demonstrated in a number of animal
models of PD, following intracerebroventricular
(i.c.v.) administration of group III agents. The ﬁrst
studies of this kind demonstrated the efﬁcacy of
i.c.v. injections of the broad spectrum agonists
L-AP4 or L-SOP against reserpine-induced akinesia
(Valenti et al., 2003; MacInnes et al., 2004), against
haloperidol-induced catalepsy and against forelimb
akinesia in the 6-OHDA lesioned rat (Valenti et al.,
2003). Of importance, the degree of reversal of fore-
limb asymmetry produced by L-AP4 following this
route of administration was similar to that pro-
duced by the gold-standard drug for treating PD,
L-DOPA, adding strength to the potential for a
useful clinical outcome in the future with this
approach. The identity of the receptor subtype(s)
mediating the responses following i.c.v. injection
has so far only been partly addressed. Following
i.c.v. injection, PHCCC was found to reverse
reserpine-induced akinesia (Marino et al., 2003)
indicating that mGlu4 receptors were useful targets
for providing anti-parkinsonian relief. Further
support for targeting mGlu4 receptors has come
from studies showing a similar reversal of reserpine-
induced akinesia and haloperidol-induced catalepsy
following i.c.v. injection of the novel mGlu4
PAM (+/-)-cis-2-(3,5,dichlorphenylcarbamoyl)cyclo-
hexanecarboxylic acid (VU0155041) (Niswender
et al., 2008a). Offering most promise from a thera-
peutic perspective are the outcomes of studies uti-
lizing systemic routes of administration. Battaglia
et al. (2006) ﬁrst showed that systemic administra-
tion of the mGlu4 PAM PHCCC could reverse
reserpine-induced akinesia. Since then, both the
broad spectrum agonist ACPT-I (Lopez et al., 2008)
and the novel mGlu4 orthosteric agonist LSP1-2111
(Beurrier et al., 2009) have been shown to reverse
haloperidol-induced catalepsy following systemic
injection. The ability of selective mGlu7 or 8 ago-
nists (or PAMs) to relieve symptoms in animal
models of PD following i.c.v. injection has not yet
been examined, although systemic administration
of a mixed mGlu8 agonist/AMPA antagonist
(R,S)-3,4-DCPG increased haloperidol-induced cata-
lepsy (Ossowska et al., 2004). While this ﬁnding
throws doubt on the anti-parkinsonian potential of
mGlu8 receptors, judgement must be delayed until
studies with ‘cleaner’ mGlu8 agonists have been
undertaken.
Neuroprotection afforded by group III
mGlu receptor activation
The ﬁnding that broad spectrum group III mGlu
agonists like L-AP4 could inhibit glutamatergic drive
to the SNc (Wigmore and Lacey, 1998), coupled with
the proposed contribution of glutamate-mediated
excitotoxicity in the progressive SNc degeneration
in PD (Blandini et al., 1996; Rodriguez et al., 1998),
make a clear case for considering the therapeutic
potential of targeting group III mGlu receptors to
bring about neuroprotection in PD.
Few groups have so far examined the potential
protective effects of group III mGlu receptor activa-
tion in animal models of PD, but all have demon-
strated favourable outcomes. Vernon et al. (2005,
2007) found that injections of the broad spectrum
group III mGlu agonist L-AP4 into the rat SNc 1 h
before toxin and for 3 or 7 days thereafter can
protect against 6-OHDA-induced nigrostriatal tract
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ervation of striatal dopaminergic neurone markers,
for example, tyrosine hydroxylase (TH), protection
of TH-positive cells in the SNc and preservation
of striatal dopamine content – were lost with con-
comitant administration of a group III mGlu recep-
tor antagonist, conﬁrming they were receptor
mediated. Studies in this laboratory have recently
conﬁrmed this protective effect of sub-chronic treat-
ment with L-AP4 against 6-OHDA-induced nigros-
triatal tract degeneration and have additionally
revealed that the motor behaviour of animals is also
preserved under this treatment regimen (Austin
et al., 2010). Although the identity of the receptor
subtype mediating this protection was not exam-
ined in these reports, our preliminary data support a
role for mGlu4 receptors, since the mGlu4 PAM,
VU0155041, provides protection against a similar
6-OHDA lesion, preserving histological and neuro-
chemical markers of dopaminergic neurones as well
as protecting against the loss of motor function
(Betts et al., 2009). This ﬁnding is consistent with
those of Battaglia et al. (2006) who found that sys-
temic injections of the mGlu4 PAM PHCCC, given
30 min before toxin injection, offered around
50% protection against 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP)-induced loss of striatal
dopamine content and reduction in TH-positive cell
numbers in the SNc in mice. In this MPTP study, a
similar protection against MPTP-induced degenera-
tion was seen following injection of PHCCC directly
into the GP. This ﬁnding implies that normalization
of glutamatergic drive to the SNc, either directly by
actions in the SNc itself or indirectly via correction
of GP ﬁring and subsequent downstream reductions
in STN glutamatergic drive to the SNc, can produce
therapeutic relief in these animal models of PD.
Studies investigating the neuroprotective potential
of activating mGlu7 or mGlu8 receptors are now
eagerly awaited as are studies involving the protec-
tive potential following systemic administration of
group III modulators.
Potential mechanisms underlying
neuroprotective effects
On the question of what events might underpin
group III mGlu receptor-mediated neuroprotection,
a number of mechanisms are proposed on the basis
of current evidence (Figure 2). The electrophysi-
ological and transmitter release data certainly point
towards direct or indirect inhibition of glutamate
release in the SNc being a key inﬂuence. However,
there are a number of other tangible explanations
that have arisen out of in vitro studies designed to
examine the mechanisms underlying group III
mGlu receptor-mediated protection. Although
many early clues were gained from studies per-
formed in other cell types, such as cortical or hip-
pocampal neurones, discussion here will focus
mainly on the studies performed in primary ventral
mesencephalic (VM) cultures encompassing
TH-positive, dopaminergic neurones. From these
studies, the two most compelling alternative expla-
nations involve activation of group III mGlu recep-
tors either on glial cells supporting the SNc
neurones or on the SNc neurones themselves.
So far, mGlu4 and mGlu7 receptors have been
identiﬁed on primary cultured rat astrocytes
(Besong et al., 2002; Yao et al., 2005) and mGlu4 and
mGlu8 receptors on rat brain microglia, which were
devoid of mGlu7 receptor expression (Taylor et al.,
2003). Exposure of astrocytes to activators such as
lipopolysaccharide (LPS) is known to trigger the
release of glial mediators such as glutamate, nitric
oxide and hydrogen peroxide that are toxic to
dopaminergic neurones (McNaught and Jenner,
2000). Indeed, conditioned medium from LPS-
treated astrocytes has been shown to cause neuronal
cell death or apoptosis in primary VM cultures
(McNaught and Jenner, 1999; Zhou et al., 2006). Of
great signiﬁcance, Zhou et al. (2006) found that con-
comitant exposure of the LPS-treated astrocytes to
the broad spectrum group III mGlu receptor agonist
L-AP4 protects VM cultures from LPS-conditioned
medium-induced apoptosis. L-AP4 was further
found to enhance glutamate re-uptake into the
treated astrocytes, secondary to producing recovery
of the astrocyte levels of the antioxidant, reduced
glutathione (Zhou et al., 2006). Astrocyte activation
is also implicated in MPTP-induced degeneration of
dopaminergic neurones. Thus, conditioned medium
from astrocytes exposed to the toxic pyridinium ion
1-methyl-4-phenylpyridinium (MPP
+) was toxic to
midbrain neuronal cultures (Yao et al., 2005). Like
LPS, MPP
+ was found to reduce glutamate uptake
into astrocytes and concomitant exposure to L-AP4
was again able to restore astrocyte glutamate uptake
and reduce the toxicity of the conditioned medium
(Yao et al., 2005). Reducing prevailing glutamate
levels in the SNc by enhancing reuptake of
glutamate into surrounding astrocytes may there-
fore be a key mechanism underpinning the neuro-
protective potential of group III mGlu receptor
activation. It is noteworthy that the related group II
mGlu receptors, which also couple through Gi/o
have been shown to produce an up-regulation
of the glial glutamate transporters GLT-1 and
GLAST through a mitogen-activated protein
(MAP) kinase and phosphatidyl-inositol-3 (PI-3)
kinase-dependent pathway (Aronica et al., 2003).
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receptors has similarly been shown to stimulate
MAP kinase and PI-3 kinase pathways in cultured
cerebellar granule cells (Iacovelli et al., 2002), so it
remains a possibility that a similar up-regulation of
glial glutamate transporters may underlie the
enhanced astrocyte glutamate uptake reported in
the above studies. L-AP4 treatment of astrocytes has
also been shown to reduce the production of pro-
inﬂammatory chemokines (Besong et al., 2002), an
effect abolished in astrocyte cultures from mGlu4 -/-
mice, indicating that activation of astoglial mGlu4
receptors may offer additional anti-inﬂammatory
actions. Although these mechanisms have yet to be
explored in animal models of PD, given that gliosis
and inﬂammation are increasingly recognized as
features of PD pathology (Whitton, 2007), it is very
likely that some component derived from activation
of astroglial group III mGlu receptors contributes to
the overall protective potential of targeting these
receptors in PD.
The remaining and undoubtedly more contro-
versial piece of the mechanistic jigsaw stems from
a study which showed that L-AP4 could protect
TH-positive neurones in rat embryonic midbrain
cultures against the toxicity of rotenone (Jiang et al.,
2006). Rotenone is known to inhibit mitochondrial
complex I (like MPTP) and to cause depolymeriza-
tion of microtubules, the latter effect having been
critically linked to the toxic capacity of rotenone on
dopaminergic neurones (Ren et al., 2005). Although
not as widely used as MPTP or 6-OHDA, rotenone
has recently been used to trigger dopaminergic
neurone death both in vitro (Falk et al., 2009) and in
vivo (Panov et al., 2005). The protective effects of
L-AP4 against rotenone toxicity again appeared to
involve activation of the MAP kinase pathway since
L-AP4 increased activation of the MAP kinase extra-
cellular signal-regulated kinase in these midbrain
TH-positive neurone cultures and the protection
against rotenone toxicity was blocked by pharmaco-
logical inhibition of MAP kinase kinase (Jiang et al.,
2006). Inhibition of MAP kinase kinase also pre-
vented L-AP4-induced attenuation of rotenone-
induced microtubule depolymerization, leading the
authors to conclude that L-AP4 provided protection
of midbrain TH-positive neurones through activa-
tion of the MAP kinase pathway to stabilize micro-
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Figure 2
Putative mechanisms underlying the protection of dopaminergic substantia nigra pars compacta (SNc) neurones following group III metabotropic
glutamate (mGlu) receptor activation. Activation of group III mGlu receptors located at three different sites in the glutamatergic subthalamonigral
synapse may underlie the protection of dopaminergic SNc neurones. (i) Activation of pre-synaptic mGlu4 or mGlu7 receptors will restrict the
pre-synaptic Ca
2+ entry required for glutamate release leading in turn to reduced synaptic glutamate levels and reduced stimulation of
post-synaptic NMDA receptors. The resultant reduction in Ca
2+ entry into SNc neurones is proposed to reduce excitotoxic damage. (ii) Activation
of glial mGlu4, 7 or 8 receptors may lead, via activation of MAP kinase or elevation of the antioxidant reduced glutathione (GSH) levels, to
increased glutamate uptake via GLT-1 or GLAST glutamate transporters, further reducing synaptic glutamate levels. Activation of glial receptors
may also reduce the production of inﬂammatory mediators, such as chemokines, that in turn will reduce the inﬂammatory stress upon SNc
neurones. (iii) Activation of mGlu4 or mGlu8 receptors on SNc neurones directly may lead to increased microtubule stabilization through a MAP
kinase-dependent pathway. One or more of these events may contribute to the overall neuroprotective effects of group III mGlu receptor
activation. G, glutamate; MAP kinase, mitogen-activated protein kinase.
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interesting about this study is that, given that the
cells were incubated in a cytosine arabinoside-
supplemented medium that inhibits glial cell
growth, the ﬁndings highlight for the ﬁrst time that
targeting group III mGlu receptors on the dopamin-
ergic neurones themselves, rather than on surround-
ing glial cells or indeed on the pre-synaptic
terminals of incoming glutamatergic neurones, can
offer neuroprotection. To date, very little is known
about a likely post-synaptic action of group III mGlu
receptors in the SNc. While current evidence rules
out the presence of mGlu7 receptors in the SNc
[with negligible mRNA or mGlu7 immunoreactivity
detected in the SNc (Kosinski et al., 1999; Messenger
et al., 2002) ], a post-synaptic presence for mGlu4 or
mGlu8 receptors cannot be entirely ruled out since
mRNA (Messenger et al., 2002) and immunoreactiv-
ity (Gu et al., 2003) for each has been reported in
this region. However, Wigmore and Lacey (1998)
failed to detect any direct post-synaptic effects of
L-AP4 on SNc neurones, despite observing the afore-
mentioned inhibition of STN-evoked EPSCs in the
SNc, reﬂective of L-AP4’s pre-synaptic action. Subse-
quent electrophysiological studies of Valenti et al.
(2005) also ruled out any post-synaptic action of
L-AP4 in regulating SNc neuronal excitability.
Future studies are therefore required to clarify
whether mGlu4 or mGlu8 receptors might mediate
any post-synaptic action, distinct from modulation
of neuronal excitability, which might relate to this
potential neuroprotective effect.
Future directions
One of the main drawbacks of long-term treatment
with L-DOPA is the onset of disabling, excessive
involuntary movements or LIDs. Future studies
should aim to examine whether, when given alone,
group III mGlu agents evoke unwanted dyskinetic
effects, akin to LIDs or whether, as seen recently
with group I mGlu5 receptor antagonists in rodents
(Rylander et al., 2009; Yamamoto and Soghomo-
nian, 2009) and primates (Johnston et al., 2010),
these agents may actually be helpful in reducing
LIDs when given in combination with low-dose
L-DOPA. It is still too early to say whether activa-
tion of group III mGlu receptors offer any degree
of long-term potential in the treatment of PD;
however, the advent of improved systemically
active drugs that are more amenable for long-term
administration to animals should enable due atten-
tion to be paid to these issues in the future. Further
studies examining the long-term effectiveness of
targeting group III mGlu receptors will also clarify
whether receptor desensitization will have any
bearing on the long-term utility of this approach.
Certainly, many of the responses noted above with
the broad spectrum agonists, ranging from electro-
physiological responses in vitro through to behav-
ioural responses and neuroprotection in vivo, show
that responses tail off at the higher concentrations
or doses tested (e.g. Valenti et al., 2003; MacInnes
et al., 2004; Vernon et al. 2007). These observations
may be explained by receptor desensitization since
the broad spectrum agonist L-AP4 has been shown
to induce rapid internalization of at least two of
the group III mGlu receptors in vitro, mGlu4 (Iacov-
elli et al., 2004) and mGlu7 (Pelkey et al., 2005).
Targeting the allosteric sites of receptors is likely to
reduce the chance of desensitization becoming a
problem (Kew, 2004) and may explain the recent
emphasis on developing mGlu4 receptor PAMs
(Niswender et al., 2008b; Engers et al., 2009;
Williams et al., 2009).
To date, investigations in the group III mGlu
receptor ﬁeld have still not progressed into the ﬁnal
preclinical model of PD, the MPTP-treated primate.
This model is the most clinically relevant model in
which to monitor the long-term effectiveness of
agents given alone or in combination with low-dose
L-DOPA. As such, studies in the MPTP-treated
primate will provide invaluable insight into the
likely clinical potential of targeting group III mGlu
receptors in PD as well as revealing any unforeseen
side effects that may arise from this strategy. Given
that combating excessive glutamatergic transmis-
sion with the use of ionotropic glutamate receptor
antagonists is predicted to lead to unacceptable
cognitive and psychomimetic adverse effects (Korn-
huber and Weller, 1997), it will be essential to estab-
lish whether targeting group III mGlu receptors to
achieve, among other things, such inhibition of
glutamatergic transmission can happen without the
occurrence of similar adverse effects. Despite the
lack of current data for group III mGlu agonists,
recent clinical trials conducted with agonists of the
related class of group II (mGlu2 and mGlu3) recep-
tors in patients with schizophrenia or generalized
anxiety disorder have reported good tolerance,
improvements in symptoms and, most importantly
here, no major treatment-related adverse events
(Patil et al., 2007; Dunayevich et al., 2008). While
the outcome of longer-duration clinical trials is still
awaited, these earliest observations of targeting
group II mGlu receptors in humans do offer hope
that drugs targeting group III mGlu receptors might
prove to be equally well tolerated and devoid of
unwanted adverse effects. However, the challenge
of producing ‘hit-to-lead’ compounds for group III
mGlu receptors with agreeable systemic activity
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tional progress in this area.
Potential added value of targeting
group III mGlu receptors in PD
In closing, it is worth turning our attention back to
the clinical situation. As mentioned in the Introduc-
tion, in addition to the classical motor symptoms of
PD, patients also exhibit a variety of non-motor
symptoms which add to their reduced quality of life.
Of these, depression and pain are particularly prob-
lematic. It is therefore promising to note that group
III mGlu receptor activation following i.c.v. admin-
istration of the broad spectrum agonists like ACPT-I
or the mGlu4 PAM PHCCC in combination with
low-dose ACPT-I has been shown to produce anti-
depressant effects in rats (Palucha et al., 2004; Klak
et al., 2007). Equally promising are the reports that
intrathecal administration of ACPT-I or PHCCC or
systemic administration of the mGlu8 agonist (S)-
DCPG relieved hyperalgesia in inﬂammatory pain
models (Marabese et al., 2007; Goudet et al., 2008),
most likely through inhibition of glutamate release
from primary afferents in the spinal cord (Zhang
et al., 2009). Finally, activation of group III recep-
tors, especially mGlu7, has been shown to inhibit
glutamate release onto dopaminergic neurones in
the ventral tegmental area, and systemic injection
of ACPT-I has been shown to produce antipsychotic
effects in rodents (Palucha-Poniewiera et al., 2008).
This portfolio of actions raises the possibility that,
in addition to combating the motor symptoms and
progressive degeneration of dopaminergic neurones
in PD, targeting group III mGlu receptors may also
provide a means of tackling some of the non-motor
signs in PD and help to stave off treatment-related
addictive behaviours or psychosis. These offer excit-
ing prospects for drug discovery in the group III
mGlu receptor ﬁeld in relation to the treatment
of PD.
Concluding remarks
In the 10 years since Bradley et al. (1999) ﬁrst dem-
onstrated immunoreactivity for group III mGlu
receptors in the basal ganglia motor loop, we have
seen the potential of targeting these receptor for
therapeutic gain ﬂourish from mere speculation
to something tangible. Activation of pre-synaptic
group III mGlu receptors has been shown to reduce
transmission across synapses in the indirect
pathway that are overactive in PD (i.e. corticostri-
atal, striatopallidal and subthalamonigral), an effect
which most likely underlies the reversal of symp-
toms seen in rodent models of the disease following
administration of agonist or PAMs of group III mGlu
receptors. Group III mGlu receptor activation has
also been shown to protect dopaminergic neurones
both in vitro and in vivo against a range of known
dopaminergic toxins. While the exact molecular
mechanisms underlying these protective effects
remain to be established, the likelihood is that ben-
eﬁcial actions are mediated through activation of
both neuronal and glial group III mGlu receptors. In
parallel ﬁelds, activation of group III mGlu receptors
has been shown to produce actions (antidepressant,
analgesic and potentially anti-addictive) that raise
the possibility that, in addition to combating the
motor symptoms and progressive degeneration of
dopaminergic neurones in PD, targeting group III
mGlu receptors may also provide a means of tack-
ling some of the non-motor signs in PD and help to
stave off treatment-related addictive behaviours or
psychosis. These results all offer exciting prospects
for drug discovery in the group III mGlu receptor
ﬁeld for the treatment of PD. Efforts should now be
directed towards elucidating which of the speciﬁc
group III mGlu receptors holds greatest potential
(with most studies to date favouring mGlu4 recep-
tors), unravelling the molecular mechanisms under-
lying neuroprotection and targeting of group III
mGlu receptors in the MPTP-treated primate model
of PD in order to discover the likely long-term thera-
peutic beneﬁts of this strategy.
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